ABSTRACT
Introduction
The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease burden.
Aim
This narrative review explores the clinical relevance of non‐severe haemophilia A (focusing on moderate disease), and examines the profile of patients with, and the evidence supporting the use of prophylaxis to manage, this disease form.
Methods
A PubMed search was conducted (no language/date limits), using terms including ‘hemophilia’ or ‘haemophilia’, and ‘moderate’, ‘nonsevere’ or ‘non‐severe’, with the names of prophylactic agents.
Results
Some patients with moderate haemophilia A experience significant disease burden (in terms of bleeding frequency and joint damage), diminished health‐related quality of life and marked economic impact. In addition, variation in bleeding phenotype across disease severity levels has been recognised, such that patients with moderate disease may have a severe phenotype and experience more frequent spontaneous bleeds than those with a mild phenotype. Few studies have specifically assessed outcomes associated with prophylaxis in patients with moderate haemophilia A. However, available data suggest that prophylaxis with FVIII concentrates and non‐factor treatments (i.e. emicizumab) provides beneficial effects in terms of bleeding frequency and joint health.
Conclusion
Severity classification alone is insufficient to predict bleeding tendency, and joint bleeding and joint injury are observed in patients with moderate disease. As such, routine prophylaxis may be recommended for some patients with moderate haemophilia A.
Keywords: blood coagulation disorders, blood coagulation factors, factor VIII, haemorrhage, haemophilia A
1. Introduction
Haemophilia A is a congenital, X‐linked, recessive bleeding disorder resulting from partial or total loss of the ability to produce clotting factor VIII (FVIII) [1]. In 2022, the prevalence of haemophilia A of all severities was approximately 24.6 cases per 100,000 male births [1, 2].
Haemophilia A is classified as mild, moderate or severe based on the degree of FVIII deficiency; severe <1 IU/dL (<1% of normal), moderate 1–5 IU/dL (1% to 5% of normal), mild >5–<40 IU/dL (>5–<40% of normal) [1, 3]. Among an international cohort of almost 9000 patients with haemophilia A who were part of the World Bleeding Disorders Registry, 30% had moderate disease—almost twice the number with mild disease (16%) and lower than the proportion with severe disease (51%) [4]. Overall, data from Japan are consistent with this international evidence—an analysis of a medical records database found that 23% of patients had moderate disease, compared with 26% with mild and 50% with severe disease [5].
The hallmark of haemophilia is repeated musculoskeletal bleeding, especially into the joints, leading to progressive joint destruction and resulting in haemophilic arthropathy, chronic disability and pain [6]. While more common in patients with severe disease, those with non‐severe disease can also experience joint deterioration [6, 7, 8] and intracranial haemorrhage (ICH) [9].
Given the growing recognition that mild and moderate haemophilia A can cause significant burden despite their classification as non‐severe disease, this review aims to explore the clinical relevance of mild and moderate disease, and to analyse the profile of patients with, and the evidence supporting the use of prophylaxis to manage, non‐severe haemophilia A (with a focus on moderate disease).
Plain Language Summary
People with moderate haemophilia A have lower levels of clotting factor VIII, which can lead to bleeding episodes. Although moderate haemophilia is often considered less critical than the severe form of the disease, many patients with moderate disease still experience serious symptoms such as joint bleeding, joint damage and intracranial haemorrhage (ICH), as well as a reduced quality of life. This review summarises current evidence showing that some people with moderate haemophilia A may benefit from regular preventive treatment (called prophylaxis) to reduce bleeding and protect joint health. The review also discusses how doctors can better identify which patients are most likely to benefit from this approach, and highlights new treatment options that may make preventive care easier and more effective.
2. Materials and Methods
A search of PubMed (from database inception; no date or language limits) was performed on 8 April 2025 and updated on 12 September 2025 using search terms including ‘haemophilia’ or ‘haemophilia’, and ‘moderate’, ‘nonsevere’ or ‘non‐severe’, with the names of agents used as prophylaxis. Additional materials were identified from the reference lists of the articles retrieved by the search, and the authors’ expert knowledge of the area.
3. Literature Findings and Discussion
3.1. Clinical Relevance of Non‐severe Haemophilia A
While haemophilia A severity is classified based on FVIII level [3], and age at diagnosis and bleeding severity/frequency correlates degree of FVIII deficiency [10, 11, 12, 13], FVIII levels alone may not fully predict clinical burden. In addition, FVIII activity is commonly measured using either a one‐stage clotting assay (OSA) or a chromogenic substrate assay (CSA), and clinically relevant discrepancies between these assays have been reported in non‐severe haemophilia A [14]. Such discrepancies, which are often associated with specific F8 missense variants, may lead to misclassification of disease severity and underestimation of bleeding risk, and may therefore influence decisions regarding prophylaxis [15]. These observations further support the need to consider clinical bleeding phenotype and joint outcomes, rather than relying solely on absolute FVIII levels. The clot waveform analysis and thrombin generation assays have been shown to reflect the clinical phenotype in haemophilia A, and may be useful in identifying patients with unexpected bleeding symptoms [16]. Table 1 summarises representative studies that have investigated the clinical characteristics, bleeding phenotype, joint outcomes, and economic burden in patients with mild to moderate haemophilia A.
TABLE 1.
Selected studies reporting clinical characteristics, bleeding phenotype, joint outcomes, and economic burden in patients with mild to moderate haemophilia.
| Author/study name [Reference] | Population/Region | Selected patient population(s) | Selected outcomes | Key findings |
|---|---|---|---|---|
| DYNAMO Study, 2022 [12] | European and Canadian cohorts (included a subgroup with moderate haemophilia A) | Mild (n = 234) vs Moderate (n = 70) haemophilia A/B | Age at diagnosis, first bleed, first joint bleed; ABR, AJBR | Moderate haemophilia shows a more severe bleeding phenotype than mild, with a significantly earlier age of diagnosis (1 vs 5 yrs), first bleed (3 vs 11 yrs), and a higher ABR (0.6 vs 0.2). |
| PedNet cohort, 2024 [10] | European and non‐European cohorts (UK, Canada, Norway, Switzerland, Israel) (included a subgroup with moderate haemophilia A) | Non‐severe haemophilia A (n = 641 children) | Age at first bleed | Patients with moderate haemophilia experience their first bleed at an earlier age (median 1.4–2.0 yrs) compared to patients with mild haemophilia (≥4.8 yrs). (Figure 1) |
|
Observational study, 2011 [17] |
Dutch cohort (included a subgroup with moderate haemophilia A) | Mild/Moderate haemophilia A (n = 433) | FVIII level vs bleeding frequency | For each 1 IU/dL increase in FVIII activity, the bleeding risk decreases by 18%. Consequently, patients with moderate haemophilia (FVIII <5%) have a high risk of joint bleeds. (Figure 2) |
| den Uijl et al., 2014 [13] | Dutch cohort born before 2000 | Moderate haemophilia A/B (n = 75) | Bleed frequency, first bleed, prophylaxis need | A ‘severe‐like’ subgroup with FVIII activity of 1–2% exists within moderate haemophilia, showing significantly more bleeds compared to patients with FVIII 3–5% (ABR 2.9 vs 1.4, p = 0.02). The proportion receiving prophylaxis was also higher (39% vs 13%). |
| den Uijl et al., 2011 [38] | Dutch cohort born after 1970 (included a subgroup with moderate haemophilia A) | Patients with severe (48%), moderate (20%), and mild (32%) haemophilia A (n = 377) | Bleeding phenotype | The median age at first joint bleed was 14.2 yrs (mild), 6.7 yrs (moderate), and 1.9 yrs (severe). FVIII activity around 3% appeared to be a major turning point for clinical bleeding symptoms. |
| CHESS‐PAEDs study, 2022 [18] | European and UK cohorts (included a subgroup with moderate haemophilia A) | Moderate (n = 331) vs Severe (n = 463) haemophilia A/B (1‐17 yrs) | QoL, medical costs, societal costs | In children, clinical bleeding outcomes such as ABR distribution and the proportion of patients with problem joints (10% vs 15%) are comparable between moderate and severe haemophilia. |
| THUNDER Study, 2019 [19] | UK cohort (included a subgroup with moderate haemophilia A) | Moderate (n = 864) vs Severe (n = 1810) haemophilia A | ABR, HJHS, treatment type | ABR: Moderate 3.0 (prophylaxis), 11.0 (on‐demand); Severe 2.0 (prophylaxis), 5.0 (on‐demand). ABR and HJHS were comparable between moderate and severe haemophilia. |
| Calcaterra et al., 2025 [20] | Italian cohort | Moderate haemophilia A (on‐demand therapy) (n = 51) | Joint damage | In patients with moderate haemophilia on on‐demand therapy, 21.6% had osteochondral damage and 29.4% had synovial hypertrophy. |
| Di Minno et al., 2013 [7] (Systematic Review) | European, North American, and Asian cohorts | Moderate haemophilia A (31 studies) | Arthropathy prevalence | The prevalence of arthropathy in patients with moderate haemophilia ranged from 15% to 77%. |
| Zwagemaker et al., 2022 [6] | Dutch cohort (included a subgroup with moderate haemophilia A) | Mild/Moderate haemophilia A (n = 51) | Joint damage by joint site | On MRI assessment, joint changes, including soft‐tissue and osteochondral alterations, were observed in 71% and 35% of ankles, 71% and 20% of knees, and 19% and 0% of elbows, respectively. |
| Verhagen et al., 2024 [8] | Dutch cohort | Moderate haemophilia A/B (n = 116) | Joint impairment | 48% of patients with moderate haemophilia self‐reported joint impairment. More patients reported joint impairment if they had a ‘severe bleeding phenotype’ (characterised by a history of high bleeding frequency) vs a ‘mild bleeding phenotype’ (77% vs 47%). |
| Zanon et al., 2022 [9] | Italian cohort | Haemophilia A/B (all severities) (n = 3,077; n = 46 ICH cases) | ICH incidence | ICH incidence 0.360 (95% CI 0.270–0.480) 1,000‐persons per year. 30% of ICH cases occurred in patients with mild haemophilia and 9% in patients with moderate haemophilia. |
| Loomans et al., 2017 [21] | European and Australian cohorts treated between 1980 and 2010 | Non‐severe haemophilia A (n = 2,709) | ICH‐related mortality | The mortality rate from ICH in patients with non‐severe (mild and moderate) haemophilia was 3.5 times higher than in the general population. (Figure 3) |
| CHESS II Study, 2022 [25] | European cohort (included a subgroup with moderate haemophilia A) |
Mild (n = 110), Moderate (n = 264) vs Severe (n = 333) haemophilia A/B Haemophilia A (n = 574) |
HRQoL, economic burden | Compared to patients with mild disease (mean score = 0.78), HRQoL scores were comparably lower in patients with moderate disease (11% lower, −0.089) and severe disease (13% lower, −0.105). |
This table summarises representative studies cited in the context of this research and does not constitute a comprehensive or systematic review.
Abbreviations: ABR, Annual Bleeding Rate; AJBR, Annual Joint Bleeding Rate; FVIII, Factor VIII; HJHS, Haemophilia Joint Health Score; HRQoL, Health‐Related Quality of Life; ICH, Intracranial haemorrhage; UK, United Kingdom; yrs, years.
Diagnostic age and bleeding frequency differ between severe and non‐severe cases of haemophilia A, and even between moderate and mild cases. In the multinational European and Canadian DYNAMO study, patients with moderate haemophilia had a significantly earlier age of diagnosis, first bleed, and first joint bleed than patients with mild haemophilia, indicating a more severe bleeding phenotype (Table 1) [12]. Data from the PedNet registry, a multinational paediatric cohort from Europe, Canada, Israel and other non‐European countries, confirmed that moderate disease is associated with earlier first bleeds/joint bleeds than mild disease (Figure 1) [10]. A Dutch study reported that for every 1 IU/dL increase in FVIII levels, the risk of bleeding decreased by 18%, and that patients with moderate haemophilia (FVIII activity 1%–5%) had a higher risk of joint bleeds versus patients with mild haemophilia (FVIII activity >5%–40%; Figure 2) [17].
FIGURE 1.

Relationship between endogenous FVIII activity and age at first bleed in children with non‐severe haemophilia A (based on data from de Kovel et al., J Thromb Haemost. 2024;22:2460–2469 [10]). Box plots show the median age and 95% confidence interval for the first occurrence of any bleed (left panel) and first joint bleed (right panel) across categories of endogenous FVIII activity (1%–2%, 3%–5%, 6%–10%, 11%–15%, 16%–20%, and 21%–25%) in paediatric patients with non‐severe haemophilia A (FVIII activity 1–25%) who were not receiving prophylaxis (n = 641). Bars indicate median and interquartile range.
FIGURE 2.

Distribution of joint bleed frequency in paediatric Dutch patients with moderate and mild haemophilia A (based on data from den Uijl et al., Haemophilia. 2011;17:41–44 [17]). Histograms show the number of patients according to the total number of joint bleeds during follow‐up. The left panel represents children with moderate haemophilia A (FVIII activity 1%–5%), and the right panel represents those with mild haemophilia A (FVIII activity >5%–40%). FVIII, Factor VIII.
Some patients with moderate haemophilia A may exhibit a severe bleeding phenotype, including frequent spontaneous bleeds, regardless of their classification [3, 8]. A study of adults and children with moderate haemophilia and no FVIII inhibitors identified a ‘severe‐like’ phenotype among patients with moderate haemophilia A; these patients required prophylaxis due to high bleeding frequency, indicating a clinical profile comparable to severe haemophilia [13].
A number of studies comparing moderate with severe haemophilia A reported that the former can be associated with significant disease burden (Table 1). For example, the retrospective CHESS‐PAEDs analysis of a multinational European and United Kingdom (UK) paediatric cohort found comparable ABRs and number of problem joints per year among patients with moderate and severe disease [18]. In the UK real‐world THUNDER study, there was little difference in the frequency of bleeding or Haemophilia Joint Health Score (HJHS) between patients with moderate or severe haemophilia A, whether they were receiving routine prophylaxis or on‐demand therapy [19].
Several studies that specifically assessed joint symptoms found that patients with non‐severe haemophilia A have clinical evidence of joint disease. A cross‐sectional multicentre study from Italy reported that arthropathy (hypertrophic synovium/osteochondral degeneration) was found in 22%–29% of patients with moderate haemophilia A receiving on‐demand therapy [20], and a systematic review of 31 studies involving European, North American, and Asian populations reported a wide range of arthropathy rates (15%–77%) in patients with moderate haemophilia A [7]. Further, a Dutch national cohort of patients with moderate haemophilia reported more prevalent joint impairment among patients with a severe than a mild bleeding phenotype [8]. Thus, FVIII level classification alone may not reflect clinical severity and patients with moderate disease in terms of FVIII levels may still develop joint deterioration.
ICH is the most serious bleeding event in haemophilia, and severe haemophilia is the most relevant risk factor for ICH in children and adolescents; however, ICH has also been reported in patients with non‐severe disease [9]. An Italian registry reported that 69.6% of ICH cases occurred spontaneously, with a higher proportion of adults with mild haemophilia A (92.9%) than those with moderate to severe disease (70.6%) [9]. All patients with mild disease and 75% of patients with moderate to severe disease were treated with on‐demand therapy alone until the onset of ICH, which may support the usefulness of prophylaxis in reducing the incidence of ICH. A European and Australian multicentre cohort study found ICH to be the cause of death in 12% of patients with non‐severe haemophilia A who were treated with FVIII concentrates, and was associated with a 3.5‐fold higher mortality rate than in the general population (Figure 3) [21].
FIGURE 3.

Data from the INSIGHT study, a retrospective cohort study of all non‐severe haemophilia A patients treated with FVIII concentrates during the observation period between 1980 and 2010 in 34 participating centres across Europe and Australia [21]. ICH, intracranial haemorrhage.
Haemophilia A causes loss of functional capacity, depression, anxiety, and diminished health‐related quality of life (HRQoL) and work participation; while these outcomes tend to worsen with decreasing FVIII activity level, they are also seen across all severity levels, including in patients with moderate haemophilia A [8, 18, 22, 23, 24, 25]. HRQoL was similar between patients with moderate and severe haemophilia in a Japanese nationwide survey [26] and in a retrospective analysis of the CHESS II study, a multinational European cohort study of males aged ≥18 years with mild, moderate or severe haemophilia A or B without inhibitors [25].
Moderate haemophilia also has a significant economic impact [18, 25, 27]. In CHESS II, annual direct medical (excluding treatment) and societal costs were similarly high in patients with moderate and severe haemophilia [25].
Taken together, these findings indicate that treatment of haemophilia A should not be determined by severity alone, and that, while moderate haemophilia A may be seen as less burdensome than severe disease, moderate disease can also result in significant clinical, psychological, and economic impact. This may largely reflect the fact that FVIII activity measured using OSA and CSA does not, in some cases, accurately reflect the true clinical phenotype. The rate of prophylaxis initiation in patients with moderate haemophilia A is lower in comparison to patients with severe haemophilia, presumably reflecting the higher levels of FVIII in the moderate group [28]. This suggests that a subset of patients with moderate disease may benefit from disease management in the form of regular prophylaxis [7].
3.2. Recommendations for the Management of Moderate Haemophilia A
Recent changes to guidelines and expert opinion reflect a more holistic understanding of the impact of non‐severe haemophilia. The World Federation of Haematology (WFH) guidelines (third edition) [29] state that:
Patients with a severe haemophilia phenotype, including those with moderate haemophilia with a severe phenotype, should receive prophylaxis.
The goal of management is bleeding prevention, allowing an active life and optimal HRQoL.
The 2024 International Society on Thrombosis and Haemostasis (ISTH) Guidelines [30] affirm that:
Prophylaxis is recommended with either emicizumab or FVIII concentrate (standard or extended half‐life recombinant FVIII [rFVIII] products), rather than on‐demand therapy in patients with severe disease, as well as moderate disease, in patients with a severe bleeding phenotype, even when FVIII plasma levels are ≥2 IU/dL.
Prophylactic therapy with either emicizumab or FVIII concentrate (rather than on‐demand therapy) should be administered in patients with severe and moderately severe haemophilia A who do not have inhibitors. A series of expert opinions suggests that patient evaluation based on FVIII activity and haemorrhage risk is important for the introduction of prophylaxis in patients with moderate haemophilia A, and initiation of prophylaxis should be according to clinical criteria and risk factors [31, 32]. A Spanish expert panel developed a decision tree for evaluating the initiation of prophylaxis in patients with moderate haemophilia A [31]. Patients without inhibitors are recommended to initiate preventive therapy if they meet at least one of the following unique criteria: severe, life‐threatening bleeding; recurrence of clinically significant provoked bleeding; or joint damage [31]. Similarly, a German expert opinion recommended the initiation of prophylaxis for non‐inhibitor haemophilia when FVIII residual activity is ≤3%, or FVIII residual activity is >3% but with a severe haemorrhagic phenotype. There is also provision for initiation of prophylaxis when comorbidities or other medications cause persistently increased bleeding tendency, or when a patient has risk factors for severe haemorrhage or joint disorders [32]. A UK expert opinion suggests that patients classified as having moderate haemophilia A should receive prophylaxis based on the same criteria as patients with severe disease [33].
Expert groups have recommended that to improve joint health and prognosis it is important to maintain high FVIII activity levels, and treatment should be individualised [34, 35, 36]. A Delphi consensus statement from 11 international experts recommended individualising target FVIII levels based on patient characteristics including bleeding phenotype, to optimise bleeding prevention [34]. Similarly, a Delphi consensus from the UK recommended that patients with moderate haemophilia A should receive preventive therapy to maintain joint health, aiming for an FVIII level of ≥15 IU/dL if there is no treatment burden, and long‐term maintenance levels of 20–30 IU/dL to better prevent bleeding or 50–150 IU/dL to prevent joint bleeding [36].
Based on evidence of an association between prophylaxis targeting higher FVIII activity levels and improved outcomes, it has been suggested that maintaining FVIII activity levels at 15%–50% may be necessary to achieve close to zero joint bleeds and improved joint health, although this might be associated with a high treatment burden [35]. A suggested approach to reduce this burden was the use of treatments that maintain elevated FVIII levels with low‐frequency administration [35].
The authors of a systematic review of literature published between 1962 and 2020 concluded that prophylaxis with standard half‐life FVIII may be useful for some patients with moderate haemophilia A [37]. In addition, early prophylaxis may be appropriate for children with moderate haemophilia A who experience joint bleeding before the age of 5 years [37].
Due to the variability in bleeding phenotype seen in patients with moderate haemophilia A, it has been recommended that the decision to start prophylaxis be based on bleeding pattern rather than endogenous FVIII levels [38].
3.3. Rationale for Prophylaxis in Moderate Haemophilia A
In our view, there has been a historic underestimation of the clinical consequences for patients with haemophilia classified as moderate. There has been delayed initiation and less frequent use of prophylaxis, and consequently joint damage, in this patient group; this supports the need for a revised clinical approach to patients with moderate haemophilia [39].
Preventive therapy for selected patients with moderate haemophilia A may be effective [40]. Some studies have outlined the consequences of not using prophylaxis in moderate haemophilia despite its benefits. A cross‐sectional study from the Netherlands found that patients with moderate haemophilia with a severe phenotype who were treated on demand had a higher median ABR (7 vs 2) and AJBR (3 vs 0), and were more likely to have joint impairment (77% vs 70%; Figure 4) than patients using prophylaxis; this difference reached statistical significance for ABR (p < 0.0001) [8]. T‐score outcomes assessing HRQoL were generally better in the prophylaxis group than in the on‐demand group, except for the domain of depression [8]. Conversely, a systematic review of studies investigating the long‐term outcomes of patients with moderate haemophilia receiving prophylaxis with replacement factor products suggested that early preventive therapy was useful for maintaining joint health in patients with frequent bleeding, regardless of endogenous clotting factor level [40].
FIGURE 4.

Differences in PROMIS T‐scores between patients with moderate haemophilia A and a severe clinical bleeding phenotype treated on‐demand versus those receiving prophylaxis, from the nationwide sixth Haemophilia in the Netherlands (HiN6) cross‐sectional observational study [8]. The bars indicate the mean differences and 95% confidence intervals in T‐scores across seven domains of the PROMIS Profile‐29, comparing patients treated on‐demand versus those who received prophylaxis among severe bleeding phenotype, defined as either ABR ≥ 5, AJBR ≥ 3, or use of secondary or tertiary prophylaxis. Positive values indicate higher T‐scores for prophylaxis. Orange lines indicate the minimally important difference (MID) threshold for each domain, and arrow directions reflect better outcomes in the prophylaxis group. ABR, Annualised Bleed Rate; AJBR, Annualised Joint Bleed Rate; IQR, interquartile range.
In a systematic review of data from 2000 and 2021 on the long‐term prognosis in non‐severe haemophilia (including 2,272 patients with moderate haemophilia A), Iorio and colleagues demonstrated that only 24% of patients with moderate disease received routine prophylaxis [40]. Patients with moderate haemophilia also appear to be less likely to undergo routine prophylaxis than patients with severe disease. In the CHESS II and CHESS‐PAEDs studies, prophylaxis use was lower in moderate than severe haemophilia A: adults 8.4% versus 56.5%; children 48.2% versus 81.2%, showing particularly low rates in adults with moderate disease [41].
Patients with moderate haemophilia also begin prophylaxis later than those with severe disease. The European PedNet study found that the patients starting prophylaxis were older (5.3 vs 1.5 years, respectively) and prophylaxis was started before the age of 24 months in fewer adolescents with moderate compared with severe disease (15% vs 63%, respectively) [42]. Despite the benefits of prophylaxis, there are some limitations to its use in patients with moderate haemophilia [43]. Firstly, prophylaxis increases FVIII utilisation, which is associated with increased costs compared with on‐demand use, and expanding use into patients with moderate haemophilia will further increase costs. Secondly, although current prophylaxis regimens reduce joint damage, they do not fully prevent this in the long term. Indeed, a study investigating long‐term arthropathy development subsequent to the introduction of prophylaxis treatment in patients with haemophilia found the incidence of this manifestation to have decreased over recent decades (more so in those with severe versus moderate disease), but patients remain at risk for developing arthropathy [44]. Thirdly, prolonged use of FVIII prophylaxis or products can be hindered by venous access issues and the development of inhibitors [45] (see below).
In addition, large disparities in treatment and care for severe haemophilia have been found between high‐ and low‐income countries. In low‐income countries, a lack of healthcare infrastructure, a shortage of specialists and the burden of drug and treatment costs contribute to major healthcare challenges, including a reliance on on‐demand haemostatic treatment, implementation of transfusion‐based management and insufficient regular prophylaxis even for patients with severe haemophilia [4, 46]. In such settings, healthcare resources are often preferentially allocated to patients at the highest risk of bleeding, which creates challenges that are specific to the management of moderate haemophilia. The question of which patients should be prioritised for treatment largely depends on local healthcare infrastructure, the availability of treatment options and healthcare policies. These constraints highlight the need to interpret recommendations for the management of moderate haemophilia within a broader framework of healthcare resource allocation and equity. Even in extremely resource‐poor settings, it is important to recognise that some patients with moderate haemophilia may present with bleeding symptoms similar to those of severe disease, and the introduction of prophylaxis for these patients should be appropriately discussed according to local circumstances, in the same way as for patients with severe haemophilia.
3.4. Options for Prophylaxis in Moderate Haemophilia A
Prophylactic FVIII replacement therapy is the mainstay of haemophilia A treatment [29], which replaces the missing clotting factor using plasma‐derived or recombinant sources. However, adherence to the prophylaxis protocols, which require frequent intravenous administration, and complications related to venous access, may be problematic [47]. Furthermore, treatment with exogenous FVIII can result in the development of inhibitors, which reduces the efficacy of treatment [45, 48]. In the INSIGHT study of patients with non‐severe haemophilia A (n = 1112), overall, 5.3% of patients developed inhibitors after a median of 28 exposure days, with the risk of inhibitor development increasing with duration of exposure (to up to 13.3% after 100 days of exposure) [49]. Because certain F8 genotypes are associated with an increased risk of inhibitor development in non‐severe haemophilia A, genotyping may be clinically informative in selected patients, particularly when intensive FVIII exposure is anticipated [49]. An analysis of data from the European Haemophilia Safety Surveillance registry found an inhibitor rate for patients with non‐severe haemophilia A of 4.2 per 1000 treatment years [50].
The past decade has seen significant advances in the management of haemophilia A, which aim to overcome the problems associated with administration of standard FVIII products. Extended half‐life clotting FVIII concentrates and non‐factor products have been developed, to allow, in general, reduced treatment burden and potentially better haemostatic control than with standard half‐life FVIII concentrates [29]. The availability of these agents has significant implications for the management of the moderate phenotype, given the growing recognition of the importance of prophylaxis in non‐severe cases.
3.4.1. Extended Half‐life Factor VIII Concentrates
Prolonged/extended half‐life FVIII preparations aim to reduce the treatment burden of patients with haemophilia [29]. These agents have administration schedules that require intravenous administration two times weekly or every 3 days (as opposed to three times per week or every other day with standard half‐life FVIII) [29], although one of the most recently approved products (efanesoctocog alfa) can be administered once a week [51]. Extension of the half‐life of FVIII concentrates has been achieved by modifying the clearance of FVIII (e.g. pegylation), disrupting the interaction between FVIII and von Willebrand factor, and protecting against FVIII lysosomal degradation [52].
rFVIII products for patients with moderate/severe haemophilia A are beneficial, based on real‐world studies demonstrating high efficacy, good patient satisfaction, and good tolerability and treatment adherence [53, 54, 55, 56].
In the multinational, non‐interventional observational AHEAD study, 711 patients with moderate (n = 210) or severe haemophilia A (with or without inhibitors) received octocog alfa, of whom 582 (81.9%) received octocog alfa as prophylaxis [54]. ABRs and annualised joint bleeding rates were low across all 7 years. ABRs were similar in severe and moderate disease.
Products such as efmoroctocog alfa, a fragment crystallisable rFVIII formulation, and various PEGylated formulations (rurioctocog alfa pegol, damoctocog alfa pegol, turoctocog alfa pegol) provide a longer half‐life (14–20 h) and reduced treatment frequency versus traditional rFVIII products while preserving efficacy, which increases patient satisfaction/quality of life (QoL) [57, 58, 59].
The interim analysis of the phase IV HEM‐POWER Study, a multinational, non‐interventional, prospective cohort study conducted in Europe, the Americas, and Asia, assessed the use of damoctocog alfa pegol (mostly as prophylaxis) in 268 patients with haemophilia A, of whom 13% had moderate disease, 3% had mild disease, and 13.1% had a history of inhibitors [59]. Compared with previous treatment, damoctocog alfa pegol reduced the mean ABR for total bleeds (from 1.5 to 1.0) in patients with mild/moderate disease [59]. The proportion of these patients with no affected joints increased from 38.9% before to 85.7% after initiation of damoctocog alfa pegol [59].
In an online survey study of 46 patients with haemophilia A (60% non‐severe) without FVIII inhibitors who received turoctocog alfa pegol (for prophylaxis in 62% of the non‐severe cohort), treatment satisfaction was greater versus prior treatment in the overall cohort (95% vs 42%; p < 0.001 [data not reported by disease severity]) [57]. The main reasons for satisfaction with turoctocog alfa pegol in patients with non‐severe disease were less frequent injections and improvements in QoL, and preference for the treatment in this patient group was high (88% preferred it over their previous treatment) [57].
3.4.2. Non‐factor VIII Treatments
At the time of the literature search, clinical trial evidence supporting the use of emicizumab in patients with non‐severe haemophilia A is available; no studies of concizumab, marstacimab or fitusiran provide results specifically for this cohort.
Emicizumab is a recombinant, humanised, bispecific FVIII‐mimetic antibody [60]. Emicizumab is administered subcutaneously by injection, and can be given weekly, 2‐weekly or 4‐weekly (administration frequencies in the drug's phase 3 registrational trial, HAVEN‐6) [60]. This administration schedule may improve adherence and make emicizumab a convenient option for prophylaxis in patients with moderate haemophilia.
The international HAVEN 6 trial included patients with moderate (n = 51) or mild (n = 21) haemophilia A without inhibitory antibodies [60]. Emicizumab effectively controlled bleeding (ABR for treated bleeds 0.9; 95% confidence interval 0.55, 1.52); 67% of patients had no bleeds requiring treatment. The safety profile was good, with no AEs leading to treatment withdrawal, modification, or interruption [60].
Real‐world studies have demonstrated the efficacy of emicizumab in patients with moderate haemophilia A. In Japan, the prospective observational TSUBASA study showed low bleeding rates among patients with moderate (16.3% of the cohort) and severe disease without inhibitors, with 57% of those with moderate disease experiencing zero bleeds during the study observation period (median 675 days) [61]. A Bangladeshi study reported a reduction in median ABR from 48 to 0.0, and significant improvement in joint health scores in a cohort composed of patients with moderate (63% of patients) or severe (37% of patients) haemophilia A, with or without inhibitors, treated with emicizumab [62].
In low‐ and middle‐income countries, non‐factor products may also improve QoL and prognosis in patients with moderate haemophilia, although challenges relating to healthcare economics and cold storage requirements remain. Long‐acting, subcutaneously administered non‐factor formulations may be particularly suitable in resource‐poor healthcare settings, as their pharmacokinetic profiles enable more stable blood concentrations with minimal monitoring requirements [46].
3.4.3. Limitations of This Review
Many of the studies cited in this review reflect treatment practices in high‐resource, high‐income regions such as Europe, North America, and Japan. As such, their findings should be interpreted in the context of established access to prophylaxis, specialist haemophilia care services, and healthcare systems capable of comprehensive follow‐up.
4. Conclusions
Moderate haemophilia A has traditionally been considered to present with milder symptoms than severe cases because coagulation factor activity is higher. However, symptoms typically associated with severe cases—such as joint bleeding, joint damage and ICH—can also be observed in patients with moderate disease, and it has been shown that there is little difference in symptoms or QoL compared with severe cases. These findings suggest that disease severity classification may not fully reflect the true clinical phenotype in some cases. Therefore, relying solely on disease severity classification to predict bleeding tendencies or determine treatment decisions in patients with congenital haemophilia A is insufficient. Although challenges exist due to regional healthcare infrastructure, for some patients with moderate haemophilia A—particularly those with a ‘severe bleeding phenotype’ or ‘early joint damage’—the initiation of prophylaxis should be considered in accordance with current international guidelines and expert consensus. Additionally, for patients with a potential ‘severe bleeding phenotype’ based on family history (such as carrying genetic mutations known to cause severe bleeding despite moderate FVIII activity, or a history of severe bleeding in relatives), as well as patients for whom future risks are a concern—such as those whose bleeding risk may increase due to changes in age and lifestyle (physical activity, occupation, etc.) and who are at risk of developing ‘early joint damage’—it is important to determine the appropriateness of prophylaxis based on these risks. This review highlights the importance of prioritising personalised care in managing moderate haemophilia A. Ultimately, clinical treatment strategies should not rely solely on severity classifications.
Author Contributions
All authors contributed to the conceptualisation of the work, read and approved all drafts, and approved the final manuscript for submission.
Funding
This work was supported by Chugai Pharmaceutical Co., Ltd.
Ethics Statement
This article is a review based exclusively on previously published literature and does not report any new studies involving human participants or animals. Therefore, ethical approval and informed consent were not required.
Conflicts of Interest
Masahiro Takeyama has received honoraria from Chugai Pharmaceutical Co., Ltd., CSL Behring, Sanofi K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation, Bayer Yakuhin Ltd., and KM Biologics Co., Ltd. Atsuki Yamashita has received honoraria from Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation, Bayer Yakuhin Ltd., Novo Nordisk Pharma Ltd., and CSL Behring. Tomoko Yamaguchi has received honoraria from Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Sanofi S.A., Novo Nordisk Pharma Ltd., CSL Behring K.K., Fujimoto Pharmaceutical Corp., and Takeda Pharmaceutical Co., Ltd. Takahiro Ito, Yui Sugawara and Akiko Ioka are employed by Chugai Pharmaceutical Co., Ltd. Tazuko Tokugawa has received speaker fees from Sanofi K.K., Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Bayer Yakuhin Ltd., Pfizer Japan Inc., Fujimoto Pharmaceutical Corporation, Japan Blood Products Organization, and CSL Behring K.K.
Acknowledgements
We would like to thank Miriam Robinson who assisted in the preparation of the outline of this manuscript on behalf of Springer Health+ and Kate Palmer of Springer Health+ who assisted with the development of the first draft. This medical writing assistance was funded by Chugai Pharmaceutical Co., Ltd.
Data Availability Statement
Data sharing is not applicable to this article as no datasets were generated or analysed during its preparation.
References
- 1. World Federation of Hematology . Hemophilia. 2020. Accessed 22 August, 2025. https://elearning.wfh.org/elearning‐centres/hemophilia/.
- 2. Iorio A., Stonebraker J. S., Chambost H., et al., “Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta‐Analytic Approach Using National Registries,” Annals of Internal Medicine 171 (2019): 540–546. [DOI] [PubMed] [Google Scholar]
- 3. G. C. White, 2nd , Rosendaal F., Aledort L. M., et al., “Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor Viii and Factor Ix of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,” Thromb Haemost 85 (2001): 560. [PubMed] [Google Scholar]
- 4. Coffin D., Gouider E., Konkle B., et al., “The World Federation of Hemophilia World Bleeding Disorders Registry: Insights From the First 10,000 Patients,” Res Pract Thromb Haemost 7 (2023): 102264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Nagao A., Ioka A., Nakamura T., et al., “Burden of Congenital Hemophilia a Requiring Treatment in Japan: The Hikoboshi Study,” Res Pract Thromb Haemost 6 (2022): e12825. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Zwagemaker A. F., Kloosterman F. R., Hemke R., et al., “Joint Status of Patients With Nonsevere Hemophilia A,” Journal of Thrombosis and Haemostasis 20 (2022): 1126–1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Di Minno M. N., Ambrosino P., Franchini M., Coppola A., and Di Minno G., “Arthropathy in Patients With Moderate Hemophilia A: A Systematic Review of the Literature,” Seminars in Thrombosis and Hemostasis 39 (2013): 723–731. [DOI] [PubMed] [Google Scholar]
- 8. Verhagen M. J. A., van Balen E. C., Blijlevens N. M. A., et al., “Patients With Moderate Hemophilia a and B With a Severe Bleeding Phenotype Have an Increased Burden of Disease,” Journal of Thrombosis and Haemostasis 22 (2024): 152–162. [DOI] [PubMed] [Google Scholar]
- 9. Zanon E., Pasca S., Demartis F., et al., “Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian Emo.Rec Registry,” Journal of Clinical Medicine 11 (2022): 1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. de Kovel M. S., Escuriola‐Ettingshausen C., Königs C., Ranta S., and Fischer K., “Bleeding Phenotype According to Factor Level in 825 Children With Nonsevere Hemophilia: Data From the Pednet Cohort,” Journal of Thrombosis and Haemostasis 22 (2024): 2460–2469. [DOI] [PubMed] [Google Scholar]
- 11. Agosti P., Siboni S. M., Scardo S., Torri A., Gualtierotti R., and Peyvandi F., “Minimum Factor Viii Levels to Prevent Joint Bleeding in Mild Hemophilia A,” Blood Adv 7 (2023): 7209–7215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Kloosterman F. R., Zwagemaker A. F., Bagot C. N., et al., “The Bleeding Phenotype in People With Nonsevere Hemophilia,” Blood Adv 6 (2022): 4256–4265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. den Uijl I., Biesma D., Grobbee D., and Fischer K., “Outcome in Moderate Haemophilia,” Blood Transfus 12 (2014): s330–336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Al Moosawi M., Nicolson H., Wong S. K. W., Dallas K. L., and Jackson S., “Treatment Changes in Hemophilia a With Chromogenic Factor Viii Assay Implementation,” Res Pract Thromb Haemost 7 (2023): 100098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Cid A. R., Calabuig M., Cortina V., et al., “One‐Stage and Chromogenic Fviii:C Assay Discrepancy in Mild Haemophilia a and the Relationship With the Mutation and Bleeding Phenotype,” Haemophilia 14 (2008): 1049–1054. [DOI] [PubMed] [Google Scholar]
- 16. Matsumoto T., Shima M., Takeyama M., et al., “The Measurement of Low Levels of Factor Viii or Factor Ix in Hemophilia a and Hemophilia B Plasma by Clot Waveform Analysis and Thrombin Generation Assay,” Journal of Thrombosis and Haemostasis 4 (2006): 377–384. [DOI] [PubMed] [Google Scholar]
- 17. den Uijl I. E., Fischer K., Van Der Bom J. G., Grobbee D. E., Rosendaal F. R., and Plug I., “Analysis of Low Frequency Bleeding Data: The Association of Joint Bleeds According to Baseline Fviii Activity Levels,” Haemophilia 17 (2011): 41–44. [DOI] [PubMed] [Google Scholar]
- 18. Rodriguez‐Santana I., DasMahapatra P., Burke T., et al., “Health‐Related Quality of Life, Direct Medical and Societal Costs Among Children With Moderate or Severe Haemophilia in Europe: Multivariable Models of the Chess‐Paeds Study,” Orphanet journal of rare diseases 17 (2022): 150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Scott M. J., Xiang H., Hart D. P., et al., “Treatment Regimens and Outcomes in Severe and Moderate Haemophilia a in the Uk: The Thunder Study,” Haemophilia 25 (2019): 205–212. [DOI] [PubMed] [Google Scholar]
- 20. Calcaterra I. L., Picasso F., Valeri F., et al., “Joint Health Status in People With Moderate Hemophilia A: A Cross‐Sectional Multicenter Study,” Res Pract Thromb Haemost 9 (2025): 102737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Loomans J. I., Eckhardt C. L., Reitter‐Pfoertner S. E., et al., “Mortality Caused by Intracranial Bleeding in Non‐Severe Hemophilia a Patients,” Journal of Thrombosis and Haemostasis 15 (2017): 1115–1122. [DOI] [PubMed] [Google Scholar]
- 22. Witkop M., Wang M., Hernandez G., Recht M., Baumann K., and Cooper D. L., “Impact of Haemophilia on Patients With Mild‐to‐Moderate Disease: Results From the P‐Fiq and B‐Hero‐S Studies,” Haemophilia 27 (2021): 8–16. [DOI] [PubMed] [Google Scholar]
- 23. Cruz‐Montecinos C., Landro M. E., Cambiaggi G., Caviglia H., and Daffunchio C., “How Does Joint Impairment Affect the Functional Capacity of the Lower Limb in Early Haemophilia‐Related Arthropathy?,” Haemophilia 29 (2023): 1604–1610. [DOI] [PubMed] [Google Scholar]
- 24. Ferri Grazzi E., Becker T., Brandt S., et al., “Clinical and Humanistic Burden of Non‐Inhibitor Haemophilia a in Five European Countries: Insights From the Chess Ii Study,” Advances in Therapy 41 (2024): 3888–3904. [DOI] [PubMed] [Google Scholar]
- 25. Rodriguez‐Santana I., DasMahapatra P., Burke T., et al., “Differential Humanistic and Economic Burden of Mild, Moderate and Severe Haemophilia in European Adults: A Regression Analysis of the Chess Ii Study,” Orphanet journal of rare diseases 17 (2022): 148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Ministry of Health “Labour and Welfare (MHLW),” in Research Project on QOL in Patients With Haemophilia: FY2023 Survey Report (2024), https://hemqol2022.acsurvey.jp/result/(inJapanese).
- 27. Chowdary P., Nissen F., Burke T., et al., “The Humanistic and Economic Burden of Problem Joints for Children and Adults With Moderate or Severe Haemophilia A: Analysis of the Chess Population Studies,” Haemophilia 29 (2023): 753–760. [DOI] [PubMed] [Google Scholar]
- 28. Berntorp E., Dolan G., Hay C., et al., “European Retrospective Study of Real‐Life Haemophilia Treatment,” Haemophilia 23 (2017): 105–114. [DOI] [PubMed] [Google Scholar]
- 29. Srivastava A., Santagostino E., Dougall A., et al., “Wfh Guidelines for the Management of Hemophilia, 3rd Edition,” Haemophilia 26 (2020): 1–158. [DOI] [PubMed] [Google Scholar]
- 30. Rezende S. M., Neumann I., Angchaisuksiri P., et al., “International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Hemophilia a and B Based on the Grading of Recommendations Assessment, Development, and Evaluation Methodology,” J Thrombo and Haemost 22 (2024): 2629–2652. [DOI] [PubMed] [Google Scholar]
- 31. Álvarez Román M. T., Bonanad S., and Calvo Villas J. M., “Moderate Haemophilia A: Recommendations From a Spanish Panel of Experts,” Haemophilia 31 (2025): 39–47. [DOI] [PubMed] [Google Scholar]
- 32. Pfrepper C., Ettingshausen C. E., Klamroth R., Oldenburg J., and Olivieri M., “Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia,” Hamostaseologie 46 (2026): 206–214. [DOI] [PubMed] [Google Scholar]
- 33. Collins P. W., Obaji S. G., Roberts H., Gorsani D., and Rayment R., “Clinical Phenotype of Severe and Moderate Haemophilia: Who Should Receive Prophylaxis and What Is the Target Trough Level?,” Haemophilia 27 (2021): 192–198. [DOI] [PubMed] [Google Scholar]
- 34. Iorio A., Iserman E., Blanchette V., et al., “Target Plasma Factor Levels for Personalized Treatment in Haemophilia: A Delphi Consensus Statement,” Haemophilia 23 (2017): e170–e179. [DOI] [PubMed] [Google Scholar]
- 35. Malec L. and Matino D., “Targeting Higher Factor Viii Levels for Prophylaxis in Haemophilia A: A Narrative Review,” Haemophilia 29 (2023): 1419–1429. [DOI] [PubMed] [Google Scholar]
- 36. Laffan M., McLaughlin P., Motwani J., et al., “Expert United Kingdom Consensus on the Preservation of Joint Health in People With Moderate and Severe Haemophilia A: A Modified Delphi Panel,” Haemophilia 30 (2024): 306–319. [DOI] [PubMed] [Google Scholar]
- 37. Valentino L. A. and Khair K., “Prophylaxis for Hemophilia a Without Inhibitors: Treatment Options and Considerations,” Expert Rev Hematol 13 (2020): 731–743. [DOI] [PubMed] [Google Scholar]
- 38. den Uijl I. E., Mauser Bunschoten E. P., and Roosendaal G., “Clinical Severity of Haemophilia A: Does the Classification of the 1950s Still Stand?,” Haemophilia 17 (2011): 849–853. [DOI] [PubMed] [Google Scholar]
- 39. Castaman G., Peyvandi F., De Cristofaro R., Pollio B., and Di Minno D. M. N., “Mild and Moderate Hemophilia A: Neglected Conditions, Still With Unmet Needs,” Journal of Clinical Medicine 12 (2023): 1368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Iorio A., Königs C., Reding M. T., et al., “Prophylaxis Use of Clotting Factor Replacement Products in People With Non‐Severe Haemophilia: A Review of the Literature,” Haemophilia 29 (2023): 33–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Chowdary P., Ofori‐Asenso R., Nissen F., et al., “Disease Burden, Clinical Outcomes, and Quality of Life in People With Hemophilia a Without Inhibitors in Europe: Analyses From Chess Ii/Chess Paeds,” TH Open 8 (2024): e181–193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Schmidt D. E., Michalopoulou A., Fischer K., et al., “Long‐Term Joint Outcomes in Adolescents With Moderate or Severe Haemophilia A,” Haemophilia 28 (2022): 1054–1061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Lopez Fernandez M. F., “Limitations of Prophylactic Treatment in Patients With Hemophilia,” Blood Coagulation & Fibrinolysis 30 (2019): S22–24. [DOI] [PubMed] [Google Scholar]
- 44. van Heel D. A. M., Foppen W., and Fischer K., “Arthropathy on X‐Rays in 363 Persons With Hemophilia: Long‐Term Development, and Impact of Birth Cohort and Inhibitor Status,” Res Pract Thromb Haemost 8 (2024): 102355. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Trinchero A., Sholzberg M., and Matino D., “The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges,” Hamostaseologie 40 (2020): 311–321. [DOI] [PubMed] [Google Scholar]
- 46. El‐Sayed A. A. and Bolous N. S., “Economic Burden of Haemophilia From a Societal Perspective: A Scoping Review,” Pharmacoecon Open 9 (2025): 179–205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Aledort L., Mannucci P. M., Schramm W., and Tarantino M., “Factor Viii Replacement Is Still the Standard of Care in Haemophilia A,” Blood Transfus 17 (2019): 479–486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Hart D. P., Alamelu J., Bhatnagar N., et al., “Immune Tolerance Induction in Severe Haemophilia A: A Ukhcdo Inhibitor and Paediatric Working Party Consensus Update,” Haemophilia 27 (2021): 932–937. [DOI] [PubMed] [Google Scholar]
- 49. Eckhardt C. L., van Velzen A. S., Peters M., et al., “Factor Viii Gene (F8) Mutation and Risk of Inhibitor Development in Nonsevere Hemophilia A,” Blood 122 (2013): 1954–1962. [DOI] [PubMed] [Google Scholar]
- 50. Fischer K., Lassila R., Peyvandi F., et al., “Inhibitor Development in Nonsevere Hemophilia: Data From the European Haemophilia Safety Surveillance (Euhass) Registry,” Res Pract Thromb Haemost 9 (2025): 102887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Sobi . Altuvoct (Efanesoctocog Alfa)—Prescribing Information 2025. Accessed 28 August, 2025 https://pro.sobi.com/system/files/Altuvoct%20PI%20IE%20%28Oct%202024%29.pdf.
- 52. Abdelgawad H. A. H., Foster R., and Otto M., “Nothing Short of a Revolution: Novel Extended Half‐Life Factor Viii Replacement Products and Non‐Replacement Agents Reshape the Treatment Landscape in Hemophilia A,” Blood Reviews 64 (2024): 101164. [DOI] [PubMed] [Google Scholar]
- 53. Delumeau J.‐C., Ikegawa C., koyama C., and Haupt V., “An Observational Study of Sucrose‐Formulated Recombinant Factor Viii for Japanese Patients With Haemophilia A,” Thromb Haemost 100 (2008): 32–37. [DOI] [PubMed] [Google Scholar]
- 54. Ozelo M. C., Hermans C., Carcao M., et al., “The Effectiveness and Safety of Octocog Alfa in Patients With Hemophilia A: Up to 7‐Year Follow‐up of the Real‐World Ahead International Study,” Ther Adv Hematol 15 (2024): 20406207231218624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Santoro C., Fuh B., Le P. Q., et al., “Bay 81–8973 Prophylaxis and Pharmacokinetics in Haemophilia A: Interim Results From the Taurus Study,” European Journal of Haematology 105 (2020): 164–172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Santoro C., Fuh B., Le P. Q., et al., “Efficacy and Safety in Patients With Haemophilia a Switching to Octocog Alfa (Bay 81–8973): Final Results of the Global Real‐World Study, Taurus,” European Journal of Haematology 110 (2023): 77–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Eichler H., Nagao A., Waller J., and Stuber A., “Real‐World Experience of People With Hemophilia a Receiving Turoctocog Alfa Pegol (N8‐Gp): Results From a Patient Experience Survey,” Patient Prefer Adherence 17 (2023): 3001–3014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Franchini M. and Mannucci P. M., “The More Recent History of Hemophilia Treatment,” Seminars in Thrombosis and Hemostasis 48 (2022): 904–910. [DOI] [PubMed] [Google Scholar]
- 59. Reding M. T., Álvarez‐Román M. T., Castaman G., et al., “Interim Analyses of the Multinational Real‐World Prospective Cohort Hem‐Powr Study Evaluating the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients With Hemophilia A,” European Journal of Haematology 112 (2024): 286–295. [DOI] [PubMed] [Google Scholar]
- 60. Négrier C., Mahlangu J., Lehle M., et al., “Emicizumab in People With Moderate or Mild Haemophilia a (Haven 6): A Multicentre, Open‐Label, Single‐Arm, Phase 3 Study,” Lancet Haematology 10 (2023): e168–177. [DOI] [PubMed] [Google Scholar]
- 61. Amano K., Fujii T., Sawada A., et al., “Tsubasa Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia a Without Factor Viii Inhibitors Receiving Emicizumab,” Haemophilia 31 (2025): 703–712. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Tory S. S., Ghosh S., Nazneen H., et al., “Effectiveness of Emicizumab in Preventing Bleeding Events in Severe and Moderate Hemophilia A: A Single‐Center Experience in Bangladesh,” EJHaem 5 (2024): 39–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no datasets were generated or analysed during its preparation.
